From the U365 Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, Paris, France; Neurolab, Paris, France; EA1529/EMI9912, Service d'Hématologie, Paris, France; Service de Cytométrie, Institut Curie, Paris, France; and U404 INSERM, Lyon, France.
Tumor necrosis factor (TNF) superfamily members BAFF, or B-cell activation factor of the TNF family, and APRIL, a proliferation-inducing ligand, are involved in normal B-cell survival and differentiation. They interact with 3 receptors: BAFF-R, specific to BAFF; and TACI and BCMA, which are shared by BAFF and APRIL. We tested the potential role of these proteins in B-cell chronic lymphocytic leukemia (B-CLL) resistance to apoptosis. TACI and BAFF-R mRNAs were found in leukemic B cells. BAFF and APRIL mRNAs and proteins were detected in B-CLL leukemic cells and normal blood or tonsil-derived B lymphocytes. Yet, in contrast to normal B lymphocytes, BAFF and APRIL were expressed at the membranes of leukemic cells. Adding soluble BAFF or APRIL protected B-CLL cells against spontaneous and drug-induced apoptosis and stimulated NF-
B activation. Conversely, adding soluble BCMA-Fc or anti-BAFF and anti-APRIL antibodies enhanced B-CLL apoptosis. Moreover, a soluble form of BAFF was detected using surface-enhanced laser desorption/ionization–time-of-flight mass spectrometry (SELDI-TOF MS) in the sera of B-CLL patients but not of healthy donors. Taken together, our results indicate that B-CLL cells can be rescued from apoptosis through an autocrine process involving BAFF, APRIL, and their receptors. Inhibiting BAFF and APRIL pathways may be of therapeutic value for B-CLL treatment.
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1
BAFF and related proteins: a new therapeutic target for B-cell malignancies
Expression of BCMA TACI and BAFF-R in multiple myeloma: a mechanism for growth and survival
A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group
A picture (in the microscope) is worth a thousand words
Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes
Added challenges to gene therapy—immune responses in the setting of myeloablation
Alphastatin a 24–amino acid fragment of human fibrinogen is a potent new inhibitor of activated endothelial cells in vitro and in vivo
Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin
BAFF and related proteins: a new therapeutic target for B-cell malignancies